Deciding to invest in pharmaceutical (pharma) or biotech stocks can be confusing unless you have a strong awareness of the basic processes and products of the company and how its securities exchange on the market.
Pharmaceutical companies vary by size, and they engage in a full array of activities from research and development (R&D) to manufacturing and marketing medicines. Moreover, each pipeline serves various purposes, targeting various diseases, and it can often take years of testing and millions of dollars just to get to a point where clinical trials can be performed.
One company that is already ahead of the curve with a substantial product pipeline, IP portfolio, and clinical trials in the works is Propanc Biopharma, Inc. (“PPCBD”). Propanc is a biopharmaceutical company focused on the development of long-term therapy based on a pancreatic proenzyme formulation to prevent tumor recurrence and metastasis, the main cause of patient death from cancer.
“Our IP portfolio is a world leader in the field of administration of proenzymes for the treatment and prevention of metastatic cancer. IP is the cornerstone of any biotech company, and places us in a strong position to unlock significant value, as we plan to progress into a First-In-Human study and then hopefully towards proof of concept in a specific cancer indication, where we will then look at possible licensing opportunities,” said Dr. Julian Kenyon, Propanc’s Chief Scientific Officer. “We are firm of the opinion that our current market value does not truly reflect the advancement of our lead product, PRP, or its true potential as a breakthrough, long term treatment for aggressive and fast-spreading cancers from solid tumors by targeting and eradicating cancer stem cells.”
These biotech companies are making great progress: Propanc BioPharma, Inc. (OTCQB: PPCB), Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT), Onconova Therapeutics, Inc. (NASDAQ: ONTX), RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), Novavax, Inc. (NASDAQ: NVAX).
Propanc BioPharma, Inc. (OTCQB: PPCBD), (Market Cap: $2.753M , Share price: $2.95), Propanc BioPharma, Inc. announced on June 27th, 2019 intellectual property (“IP”) portfolio has undergone rapid growth recently, with sixty-five patents currently either in force or pending in most major countries and regions around the world. The IP covers Propanc’s underlying anti-cancer technology in development. In the past year, three additional patent families entered national phase, where a patent application is filed in individual countries and regions, in order to achieve grant status.
“Our IP portfolio is a world leader in the field of administration of proenzymes for the treatment and prevention of metastatic cancer. IP is the cornerstone of any biotech company, and places us in a strong position to unlock significant value, as we plan to progress into a First-In-Human study and then hopefully towards proof of concept in a specific cancer indication, where we will then look at possible licensing opportunities,” said Dr. Julian Kenyon, Propanc’s Chief Scientific Officer.
Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT), (Market Cap: $27.768M , Share price: $0.072), Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer and liver cancer. Provectus investigational oncology drug, PV-10, is an ablative immunotherapy under investigation in solid tumor cancers. The Company has received orphan drug designation from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for psoriasis.
Onconova Therapeutics, Inc. (NASDAQ: ONTX), (Market Cap: $14.996M, Share price: $2.50), Onconova Therapeutics is a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS. The company also develops Briciclib, which is in Phase I multisite dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. In addition, it has various product candidates in preclinical development that target kinases, cellular metabolism, or cell division.
RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), (Market Cap: $21.964M, Share price: $0.167), RegeneRx is a publicly traded, clinical-stage, biopharmaceutical company engaged in the design, research and development of novel peptides targeted at diseases with unmet medical needs. RegeneRx’s mission is to research and develop novel pharmaceuticals that protect and repair tissue and organ damage caused by disease, trauma or other pathology.
Novavax, Inc. (NASDAQ: NVAX), (Market Cap: $115.016M, Share price: $4.90), Novavax, together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company’s lead vaccine candidates include ResVax, respiratory syncytial virus (RSV) fusion (F) protein recombinant nanoparticle vaccine with aluminum phosphate as an adjuvant that is in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase II clinical trial for treating seasonal influenza in older adults. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, and the immune systems attack against microorganisms, as well as allows immunization with much lower doses of antigen.
When deciding to invest in a biotech/pharma company, it is imperative that you conduct your due diligence in selecting a strong company that has a proven track record of product success.
Propanc, for example, has a total of four patent families covering the use of proenzymes for treating cancer via a combination of trypsinogen and/or chymotrypsinogen pancreatic proenzymes, which includes Propanc’s lead product candidate, PRP. The IP portfolio includes the composition of matter claims and a method of treatment to eradicate cancer stem cells. Further applications are also expected relating to the formulation and methods of use, as well as research programs with its joint research partners designed to further optimize the quality, safety, and performance of PRP.
This article was written by Regal Consulting, LLC (“Regal Consulting”). Regal Consulting expects to be paid $3,000 for the article directly from PPCB. All payments were made directly by Propanc Biopharma, Inc. (PPCB) to Regal Consulting, LLC. to provide investor relations services, of which this article is a part of. Regal Consulting also paid one thousand dollars cash to microcapspeculators.com to distribute this article. Regal Consulting may have a position in the securities mentioned in this article at the time of publication, and may increase or decrease its position without notice. This article is based on public information and the opinions of Regal Consulting. PPCB was given an opportunity to edit this article. This article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any results predicted herein. Regal Consulting is not registered with any financial or securities regulatory authority, and does not provide or claim to provide investment advice.
Company Name: Microcap Speculators
Contact Person: Media Manager
Country: United States